Stock comparison
Haemonetics
Molina Healthcare
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
HAE
Haemonetics
Market cap
$2.88B
Sector
Healthcare
MOH
Molina Healthcare
Market cap
$9.44B
Sector
Healthcare
Overall winner
Haemonetics HAE
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | HAE | MOH | Winner |
|---|---|---|---|
| Warren Buffett | 70B | 27F | HAE |
| Benjamin Graham | 85A | 75B | HAE |
| Philip Fisher | 60C | 29F | HAE |
| Peter Lynch | 54C | 24F | HAE |
| Joel Greenblatt | 31F | 16F | HAE |
| Charlie Munger | 54D | 31F | HAE |
| Terry Smith | 55D | 25F | HAE |
Side-by-side metrics
| Metric | HAE | MOH |
|---|---|---|
| Market cap | $2.88B | $9.44B |
| P/E (TTM) | 24.8x | 50.2x |
| EV/EBIT | 14.1x | 10.6x |
| ROIC (TTM) | 8.37% | 5.27% |
| Gross margin | 55.74% | 9.59% |
| Net margin | 7.29% | 0.42% |
| Revenue CAGR 5y | 7.65% | 13.09% |
| EPS CAGR 5y | 24.62% | -5.92% |
| Debt / Equity | 1.5x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
HAE leads on
- EPS CAGR 5y24.62%vs -5.92%+124%
- Net margin7.29%vs 0.42%+94%
- Gross margin55.74%vs 9.59%+83%
- P/E (TTM)24.8xvs 50.2x+51%
MOH leads on
- Market cap$9.44Bvs $2.88B+70%
- Revenue CAGR 5y13.09%vs 7.65%+42%
- Debt / Equity1.0xvs 1.5x+37%
- EV/EBIT10.6xvs 14.1x+25%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.